Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine.
This would allow the cancer to be detected and treated by radioactive iodine.
PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function
in treating patients who have persistent or metastatic thyroid cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Lucille P. Markey Cancer Center at University of Kentucky